Navigation Links
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:3/12/2009

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME).

This 36-month, open-label, Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide (FA), after administration of Iluvien in patients with DME. Secondarily, the PK Study is designed to provide information on the safety and efficacy of Iluvien in a DME patient population. A total of 37 subjects were enrolled in the PK Study, 20 patients on the low dose of Iluvien (an approximate 0.23 micrograms per day dose), and 17 patients on the high dose of Iluvien (an approximate 0.45 micrograms per day dose).

In the 12-month interim readout, no adverse events related to intraocular pressure (IOP) were seen in low dose patients, and 23.5 percent of the high dose patients experienced IOP increases of 30 millimeters of mercury (mmHg) or greater at some time point. By way of comparison, in published results from clinical studies of DME patients using sustained release intravitreal FA in Bausch & Lomb Incorporated's product Retisert(R), a surgically implanted intravitreal drug delivery device containing 0.59 mg FA approved for the treatment of chronic non-infectious posterior uveitis, 35 percent of the patients experienced IOP increases of 30 mmHg or greater at some time point during the first year.

"This profile of IOP changes occurring only in the high dose group is consistent with the IOP change profiles that
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Armada Health Care (Armada), the ... is pleased to announce an agreement with Aurora ... of innovative specialty pharmacy patient program offerings. The ... management services to specialty patients via Armada,s proprietary ... Aurora will use the OTM platform as its ...
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 Professional Compounding ... paediatric medicine by awarding the three best scientific ... initiative (EuPFI) conference . The Formulating Better ... 18 in Athens, Greece , ... students and professionals, from which three winners will ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, today announced the introduction of the ... The black and white portable unit provides outstanding imaging ... use in numerous specialty markets. With DP-50,s launch, Mindray ...
... Cempra Pharmaceuticals today announced abstracts to be ... fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st ... , September 17 to 20, 2011, in Chicago. ... safety and routes of administration of CEM-101, a ...
Cached Medicine Technology:Mindray Introduces DP-50 Portable Ultrasound System in the U.S. 2Mindray Introduces DP-50 Portable Ultrasound System in the U.S. 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
(Date:8/21/2014)... Black mothers are less likely than white moms to ... Hospitals in neighborhoods with many black residents do less ... white residents, a U.S. government study finds. Key ... medical centers where the black population is higher than ... and Prevention reported Thursday. These practices include efforts ...
(Date:8/21/2014)... 21, 2014 The W. Montague ... and a national voice in the elimination of ... disparities during the 112th National Medical Association’s (NMA) ... included: , John Ruffin, Ph.D, former Director of ... Disparities, whose life-long career and innovations have had ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
(Date:8/21/2014)... STOCKHOLM, SWEDEN (PRWEB) August 21, 2014 ... today that this year's conference will focus on ... be expected for research, innovation and commercialization. , ... successful ventures, SALSS combines the worlds' of business ... to a widely recognized Summit, gathering a diverse ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... Reporter , MONDAY, Oct. 11 (HealthDay News) -- People with ... if they don,t have full-blown diabetes, a new study indicates. ... insulin resistance -- a reduction in the ability of the ... be helpful in preventing stroke, the researchers noted. Treating ...
... Osteoporosis Canada aimed at preventing fragility fractures in ... are published in CMAJ ( Canadian Medical Association ... "Fragility fractures, the consequence of osteoporosis, are ... and economic costs," writes Dr. Alexandra Papaioannou, McMaster ...
... the last six months of life has become progressively more ... in the United States and older adults in Canada, with ... of life in both countries, according to two reports posted ... print issue of Archives of Internal Medicine , one ...
... with blockages in the carotid artery that supplies blood ... appears to be associated with an increased risk of ... surgical treatment (carotid endarterectomy), according to a meta-analysis of ... will appear in the February 2011 print issue of ...
... treatment for retinal conditions nearly doubled between 1997 and ... most commonly performed, according to a report in the ... of the JAMA/Archives journals. "Retinal disease is highly ... (AMD) and diabetic retinopathy account for more than half ...
... the standard treatment for ovarian cancer, does not improve ... according to a study published online October 11 in ... Cisplatin plus paclitaxel, and carboplatin plus paclitaxel, are ... ovarian cancer. Still, most women relapse and die from ...
Cached Medicine News:Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 2Health News:Carotid stents associated with greater risk of stroke or death than carotid endarterectomy surgery 3Health News:Treatment of retinal conditions appears to have changed significantly in previous decade 2Health News:Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival 2Health News:Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival 3
... DXC-990 camera is a 3 chip 1/2 inch color ... and a high s/n ratio. It offers picture contrast ... and knee control. The user can choose automatic exposure ... The Sony DXC-990 camera is a bayonet mount and ...
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
... image management. Mediscan is an advanced ... derived from extensive experience with clinicians. ... organize, and distribute high quality images, ... effort. Can be connected to flexible ...
For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
Medicine Products: